Molica et al used the score of Soumerai et al (BALL score) and del17p status to predict survival of a patient with chronic lymphocytic leukemia (CLL). The authors are from Azienda Ospedaliera Pugliese-Ciaccio (Catanzaro, Italy) and University of Barcelona.
Patient selection: CLL
Parameters:
(1) low risk vs intermediate/high risk by Soumerai model
(2) del17p status
Soumerai Model
del17p
Prognostic Group
low risk
absent
1 (good)
low risk
present
2
intermediate or high risk
absent
2
intermediate or high risk
present
3 (poor)
Groups 2 and 3 diverged up until after 52 years after which they converged with 0% survival at 68 months. Group 1 had a 85% survival at 60 months.
A patient at intermediate or high risk should be considered for a combination of targeted drugs (such as ibrutinib) or cellular-based therapies.
To read more or access our algorithms and calculators, please log in or register.
